Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Explore why a budget calculator may be inaccurate and how to diagnose common sources of error, then implement corrective steps.
19,172 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
A leaked exchange allegedly shows Trump telling Netanyahu, ‘you’re crazy,’ prompting a sharp market reaction as trade...
A growth stock that surged to lofty heights last year has cooled in 2026, but big buyers keep stepping in as AI capac...
Dennis Quaid has listed his Los Angeles residence for $5.2 million as he relocates to Nashville, a move that highligh...
ClearPoint Neuro's earnings are under the microscope for investors watching the medical-device niche. This analysis b...
Bitcoin hovers near $70,000 as Iran-driven energy volatility cools and policy expectations shift, setting up a pivota...
Looking for aggressive portfolio examples that balance growth and risk? This guide provides concrete allocations, ste...
Palantir surging in July shines a contrast with Google’s cloud-driven growth. Both giants report strong quarters, but...
BlackRock CEO Larry Fink warns that AI disruption could raise unemployment among new graduates, even in a steady econ...
Oil futures climbed after the U.S. Treasury canceled a license that allowed limited Iranian oil sales, triggering a f...
As Enhabit prepares to report its first-quarter results, investors need a clear playbook. This guide breaks down what...
As hacks surge on custodial platforms in 2026, GhostSwap’s non-custodial model shows why funds never held: ghostswap’...